ATE476182T1 - Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs - Google Patents

Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs

Info

Publication number
ATE476182T1
ATE476182T1 AT05076845T AT05076845T ATE476182T1 AT E476182 T1 ATE476182 T1 AT E476182T1 AT 05076845 T AT05076845 T AT 05076845T AT 05076845 T AT05076845 T AT 05076845T AT E476182 T1 ATE476182 T1 AT E476182T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
topotecan
treatment
ovarian cancer
human
Prior art date
Application number
AT05076845T
Other languages
English (en)
Inventor
Randall Johnson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE476182T1 publication Critical patent/ATE476182T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
AT05076845T 1991-02-21 1992-02-07 Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs ATE476182T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65894891A 1991-02-21 1991-02-21

Publications (1)

Publication Number Publication Date
ATE476182T1 true ATE476182T1 (de) 2010-08-15

Family

ID=24643386

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92907833T ATE444755T1 (de) 1991-02-21 1992-02-07 Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
AT05076845T ATE476182T1 (de) 1991-02-21 1992-02-07 Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92907833T ATE444755T1 (de) 1991-02-21 1992-02-07 Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs

Country Status (13)

Country Link
EP (3) EP1690542A3 (de)
JP (1) JP2778632B2 (de)
KR (1) KR930702983A (de)
AT (2) ATE444755T1 (de)
AU (1) AU663312B2 (de)
CA (1) CA2103708C (de)
DE (2) DE69233793D1 (de)
DK (2) DK0572557T3 (de)
ES (2) ES2334178T3 (de)
HK (1) HK1012265A1 (de)
MX (1) MX9200754A (de)
PT (1) PT100156B (de)
WO (1) WO1992014469A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101255406B (zh) * 2005-04-22 2010-05-26 李红霞 人卵巢癌耐药细胞株
ES2371171B1 (es) * 2010-06-08 2012-11-16 Consejo Superior De Investigaciones Científicas (Csic) Derivados de camptotecina como agentes antitumorales.
CN102477042A (zh) * 2010-11-26 2012-05-30 复旦大学 10-羟基喜树碱衍生物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
DE69233773D1 (de) 2009-11-19
EP1707568B1 (de) 2010-08-04
JP2778632B2 (ja) 1998-07-23
EP1707568A3 (de) 2008-03-26
ES2349037T3 (es) 2010-12-22
PT100156B (pt) 1999-09-30
AU1461692A (en) 1992-09-15
EP0572557A4 (en) 1993-12-29
MX9200754A (es) 1992-08-01
EP1690542A3 (de) 2008-03-26
DK0572557T3 (da) 2010-02-01
CA2103708A1 (en) 1992-08-22
AU663312B2 (en) 1995-10-05
ATE444755T1 (de) 2009-10-15
EP0572557B1 (de) 2009-10-07
DE69233793D1 (de) 2010-09-16
CA2103708C (en) 2004-04-27
JPH06505740A (ja) 1994-06-30
EP1690542A2 (de) 2006-08-16
KR930702983A (ko) 1993-11-29
PT100156A (pt) 1993-05-31
HK1012265A1 (en) 1999-07-30
WO1992014469A1 (en) 1992-09-03
EP0572557A1 (de) 1993-12-08
DK1707568T3 (da) 2010-11-08
ES2334178T3 (es) 2010-03-05
EP1707568A2 (de) 2006-10-04

Similar Documents

Publication Publication Date Title
DE69233169D1 (de) Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
SE9301951D0 (sv) Methods for administration of taxol
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
HU0301601D0 (en) Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
ATE476182T1 (de) Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
GB8819626D0 (en) Pharmaceutical composition for treatment of tumours
PT1250926E (pt) Utilização de uma s-camptotecina insolúvel em água, com um anel de lactona fechado, no fabrico de um medicamento para o tratamento do cancro do cólon
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
ITGE910094A0 (it) Prodotto per la cura e la prevenzione del cancro e dell'aids
OA09766A (en) "Treatment of anxiety in benzodiazepine-withdrawn patients".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1707568

Country of ref document: EP